The EMA is pleased to announce the distribution of the January 2023 issue of the monthly newsletter. It contains news on new drug approvals in the areas of Covid-19 vaccines, cancer, cardiovascular medicine, hematology, hepatology, HIV, hormones, immune system, metabolism, nephrology, CNS, ophthalmology, respiratory, rheumatology, and vaccines.
It also includes several updates on clinical guidelines and a list of reports of scientific events, most of them devoted to clarifications about the new CTIS (Clinical Trials Information System), in place in all EU countries from January 2022, and which is now mandatory for all sponsors planning to activate a new clinical trial.
Access the newsletter here.
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
